{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T09:38:30Z","timestamp":1776505110505,"version":"3.51.2"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007359","name":"Fondazione Banco di Sardegna \u2013 Italy","doi-asserted-by":"publisher","award":["U629.2013\/AI.553.MGB"],"award-info":[{"award-number":["U629.2013\/AI.553.MGB"]}],"id":[{"id":"10.13039\/100007359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.neuroscience.2015.04.026","type":"journal-article","created":{"date-parts":[[2015,4,20]],"date-time":"2015-04-20T17:28:31Z","timestamp":1429550911000},"page":"23-35","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPAR\u03b3 agonist in vitro and in MPTP-treated mice"],"prefix":"10.1016","volume":"302","author":[{"given":"D.","family":"Lecca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.K.","family":"Nevin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Mulas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0367-832X","authenticated-orcid":false,"given":"M.A.","family":"Casu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Diana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Sacchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.R.","family":"Carta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2015.04.026_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.urology.2012.03.032","article-title":"Association between pioglitazone and urothelial bladder cancer","volume":"80","author":"Barbalat","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0010","first-page":"864140","article-title":"Regulation of glial cell functions by PPAR-gamma natural and synthetic agonists","volume":"2008","author":"Bernardo","year":"2008","journal-title":"PPARRes"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0015","doi-asserted-by":"crossref","first-page":"845618","DOI":"10.1155\/2012\/845618","article-title":"Classic and new animal models of Parkinson\u2019s disease","volume":"2012","author":"Blesa","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0020","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1046\/j.1471-4159.2002.00990.x","article-title":"Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson\u2019s disease","volume":"82","author":"Breidert","year":"2002","journal-title":"J Neurochem"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0025","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2174\/1389450111314070004","article-title":"PPAR-\u03b3: therapeutic prospects in Parkinson\u2019s disease","volume":"14","author":"Carta","year":"2013","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0030","first-page":"1","article-title":"Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson\u2019s disease","volume":"17","author":"Carta","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0035","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1471-4159.2009.06425.x","article-title":"Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson\u2019s disease","volume":"111","author":"Carta","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0040","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.neuroscience.2011.07.046","article-title":"Rosiglitazone decreases peroxisome proliferator receptor-\u03b3 levels in microglia and inhibits TNF-\u03b1 production: new evidences on neuroprotection in a progressive Parkinson\u2019s disease model","volume":"194","author":"Carta","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0045","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/toxsci\/kfi266","article-title":"Effects of PPARgamma and combined agonists on the urinary tract of rats and other species","volume":"87","author":"Cohen","year":"2005","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0050","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.4049\/jimmunol.168.6.2795","article-title":"Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors","volume":"168","author":"Cunard","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0055","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1046\/j.1471-4159.2003.02210.x","article-title":"Protection by pioglitazone in the MPTP model of Parkinson\u2019s disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation","volume":"88","author":"Dehmer","year":"2004","journal-title":"J Neurochem"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0060","doi-asserted-by":"crossref","first-page":"36703","DOI":"10.1074\/jbc.M004045200","article-title":"Induction of IkappaB alpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators","volume":"275","author":"Delerive","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0065","first-page":"649","article-title":"Peroxisome proliferator-activated receptors: nuclear control of metabolism","volume":"20","author":"Desvergne","year":"1999","journal-title":"Endocr Rev"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bcp.2005.03.033","article-title":"Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?","volume":"70","author":"Feinstein","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0075","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0080","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.neuroscience.2015.04.026_b9000","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/j.1471-4159.2006.04327.x","article-title":"Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system","volume":"100","author":"Hunter","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0085","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.neulet.2007.12.019","article-title":"Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague\u2013Dawley rats","volume":"432","author":"Hunter","year":"2008","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0090","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00011-010-0203-7","article-title":"PPAR\u03b3 agonist pioglitazone inhibits microglia inflammation by blocking p38 mitogen-activated protein kinase signaling pathways","volume":"59","author":"Ji","year":"2010","journal-title":"Inflamm Res"},{"key":"10.1016\/j.neuroscience.2015.04.026_b9005","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0304-3940(99)00055-5","article-title":"Activators of peroxisome proliferator-activated receptor-gamma (PPARgamma) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells","volume":"262","author":"Kitamura","year":"1999","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0095","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.2174\/13816128113199990294","article-title":"Pioglitazone and cancer: angel or demon?","volume":"19","author":"Kostapanos","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0100","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.phrs.2012.02.008","article-title":"Differential susceptibility to the PPAR-\u03b3 agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson\u2019s disease","volume":"65","author":"Laloux","year":"2012","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0105","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.nurt.2008.05.003","article-title":"PPARgamma agonists as therapeutics for the treatment of Alzheimer\u2019s disease","volume":"5","author":"Landreth","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0110","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.toxlet.2012.07.016","article-title":"Rosiglitazone, a PPAR-\u03b3 agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats","volume":"213","author":"Lee","year":"2012","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/0300060513476601","article-title":"Peroxisome proliferator-activated receptor-\u03b3 agonist rosiglitazone reduces secondary damage in experimental spinal cord injury","volume":"41","author":"Li","year":"2013","journal-title":"J Int Med Res"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0120","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.pneurobio.2009.08.001","article-title":"The influence of microglia on the pathogenesis of Parkinson\u2019s disease","volume":"89","author":"Long-Smith","year":"2009","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0125","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1523\/JNEUROSCI.0172-13.2013","article-title":"Targeting Alzheimer\u2019s pathology through PPAR\u03b3 signaling: modulation of microglial function","volume":"33","author":"Lourenco","year":"2013","journal-title":"J Neurosci"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0130","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1074\/jbc.M414390200","article-title":"Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation","volume":"280","author":"Luna-Medina","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0135","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0165-1161(83)90010-9","article-title":"Revised methods for the Salmonella mutagenicity test","volume":"113","author":"Maron","year":"1983","journal-title":"Mutat Res"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0140","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.pharmthera.2005.08.007","article-title":"Peroxisome proliferator-activated receptors and inflammation","volume":"110","author":"Moraes","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0145","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neuroscience.2003.08.064","article-title":"Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS","volume":"123","author":"Moreno","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0150","doi-asserted-by":"crossref","first-page":"a009381","DOI":"10.1101\/cshperspect.a009381","article-title":"Inflammation and adaptive immunity in Parkinson\u2019s disease","volume":"2","author":"Mosley","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0155","series-title":"Principles and practices of unbiased stereology: an introduction for bioscientists","author":"Mouton","year":"2002"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0160","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.1021\/jm300068n","article-title":"Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds","volume":"55","author":"Nevin","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0165","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.molmed.2012.12.003","article-title":"Parkinson\u2019s disease in the nuclear age of neuroinflammation","volume":"19","author":"Nolan","year":"2013","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0170","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/25931","article-title":"Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma","volume":"395","author":"Nolte","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0175","doi-asserted-by":"crossref","first-page":"752","DOI":"10.2174\/1389450111314070005","article-title":"PPARs: a potential target for a disease-modifying strategy in stroke","volume":"14","author":"Ouk","year":"2013","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0180","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1124\/jpet.106.113472","article-title":"Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats","volume":"320","author":"Park","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0185","series-title":"The mouse brain in stereotaxic coordinates","author":"Paxinos","year":"2001"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0190","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0306-4522(01)00295-0","article-title":"Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP\/probenecid treatment","volume":"106","author":"Petroske","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0195","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.nbd.2014.08.011","article-title":"Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-\u03b3 agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson\u2019s disease","volume":"71C","author":"Pisanu","year":"2014","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0200","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.expneurol.2013.05.014","article-title":"A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson\u2019s disease and potential molecular targets","volume":"256","author":"Ramsey","year":"2014","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0205","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature09615","article-title":"The myeloid cells of the central nervous system parenchyma","volume":"468","author":"Ransohoff","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0210","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nprot.2008.75","article-title":"Neutral red uptake assay for the estimation of cell viability\/cytotoxicity","volume":"3","author":"Repetto","year":"2008","journal-title":"Nat Protoc"},{"issue":"6765","key":"10.1016\/j.neuroscience.2015.04.026_b0215","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/47520","article-title":"Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase","volume":"403","author":"Rossi","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0220","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jneuroim.2012.03.010","article-title":"Full and partial peroxisome proliferation-activated receptor-\u03b3 agonists, but not \u03b4 agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression","volume":"246","author":"Sadeghian","year":"2012","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0225","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(14)61010-2","article-title":"Slowing of neurodegeneration in Parkinson\u2019s disease and Huntington\u2019s disease: future therapeutic perspectives","volume":"384","author":"Schapira","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0230","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12640-009-9061-x","article-title":"Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson\u2019s disease","volume":"16","author":"Schintu","year":"2009","journal-title":"Neurotox Res"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0235","doi-asserted-by":"crossref","first-page":"22925","DOI":"10.1074\/jbc.M414635200","article-title":"Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo","volume":"280","author":"Shih","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0240","doi-asserted-by":"crossref","unstructured":"Skerrett R, Malm T, Landreth G (2014) Nuclear receptors in neurodegenerative diseases. Neurobiol Dis [Epub ahead of print].","DOI":"10.1016\/j.nbd.2014.05.019"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0245","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.it.2007.09.003","article-title":"Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms","volume":"28","author":"Straus","year":"2007","journal-title":"Trends Immunol"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0250","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1073\/pnas.97.9.4844","article-title":"15-Deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway","volume":"97","author":"Straus","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0255","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.neuint.2006.03.020","article-title":"PPARgamma as a therapeutic target in central nervous system diseases","volume":"49","author":"Sundararajan","year":"2006","journal-title":"Neurochem Int"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0260","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1179\/1743132813Y.0000000305","article-title":"Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates","volume":"36","author":"Swanson","year":"2014","journal-title":"Neurol Res"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0265","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1742-2094-8-91","article-title":"The PPAR-\u03b3 agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys","volume":"8","author":"Swanson","year":"2011","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0270","doi-asserted-by":"crossref","first-page":"582809","DOI":"10.1155\/2013\/582809","article-title":"Neuroprotective properties of a novel non-thiazoledinedione partial PPAR- \u03b3 agonist against MPTP","volume":"2013","author":"Swanson","year":"2013","journal-title":"PPAR Res"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0275","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.nbd.2009.11.004","article-title":"Neuroinflammation in Parkinson\u2019s disease: its role in neuronal death and implications for therapeutic intervention","volume":"37","author":"Tansey","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0280","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/10590501.2012.735519","article-title":"Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies","volume":"30","author":"Tseng","year":"2012","journal-title":"J Environ Sci Health C Environ Carcinog Ecotoxicol Rev"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0285","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1471-4159.2006.04376.x","article-title":"Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents","volume":"101","author":"Tureyen","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0290","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/bcp.12306","article-title":"Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis","volume":"78","author":"Turner","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0295","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.bbadis.2011.02.014","article-title":"PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation","volume":"1812","author":"Varga","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0300","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1046\/j.1471-4159.2000.740721.x","article-title":"Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP","volume":"74","author":"Vila","year":"2000","journal-title":"J Neurochem"},{"key":"10.1016\/j.neuroscience.2015.04.026_b0305","article-title":"Pleiotropic role of PPAR\u03b3 in intracerebral hemorrhage: an intricate system involving Nrf2, RXR, and NF-\u03baB","author":"Zhao","year":"2014","journal-title":"CNS Neurosci Ther"}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030645221500367X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030645221500367X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T05:25:48Z","timestamp":1537680348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030645221500367X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":63,"alternative-id":["S030645221500367X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2015.04.026","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}